## Gabriella d'Ettorre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4105752/publications.pdf

Version: 2024-02-01

211 papers

4,460 citations

32 h-index 52 g-index

213 all docs

213 docs citations

213 times ranked

6818 citing authors

#	Article	IF	Citations
1	Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 601.	1.2	187
2	Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients, 2020, 12, 1718.	1.7	155
3	Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Frontiers in Medicine, 2020, 7, 389.	1.2	152
4	Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV―Clinical Trial. PLoS ONE, 2015, 10, e0137200.	1.1	120
5	Nox2 activation in Covid-19. Redox Biology, 2020, 36, 101655.	3.9	114
6	HIV-Associated Immune Activation: From Bench to Bedside. AIDS Research and Human Retroviruses, 2011, 27, 355-364.	0.5	105
7	Post-traumatic Stress Disorder Among COVID-19 Survivors at 3-Month Follow-up After Hospital Discharge. Journal of General Internal Medicine, 2021, 36, 1702-1707.	1.3	98
8	Probiotic supplementation promotes a reduction in Tâ€cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ARTâ€treated HIVâ€1â€positive patients. Immunity, Inflammation and Disease, 2017, 5, 244-260.	1.3	84
9	Soluble ligands for the NKG2D receptor are released during HIV†infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB Journal, 2013, 27, 2440-2450.	0.2	75
10	Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nature Medicine, 2007, 13, 1431-1439.	15.2	74
11	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. Current HIV Research, 2011, 9, 148-153.	0.2	68
12	Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?. Journal of Infection and Chemotherapy, 2013, 19, 732-739.	0.8	65
13	Retinal involvement and ocular findings in COVID-19 pneumonia patients. Scientific Reports, 2020, 10, 17419.	1.6	65
14	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Journal of Antimicrobial Chemotherapy, 2017, 72, dkw557.	1.3	62
15	Hypoalbuminemia, Coagulopathy, and Vascular Disease in COVID-19. Circulation Research, 2020, 127, 400-401.	2.0	60
16	Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. Journal of Medical Virology, 2003, 69, 1-6.	2.5	59
17	Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. Aids, 2002, 16, 181-188.	1.0	56
18	Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Frontiers in Nutrition, 2020, 7, 613928.	1.6	55

#	Article	IF	CITATIONS
19	Hospital-acquired infection surveillance in a neonatal intensive care unit. American Journal of Infection Control, 2009, 37, 201-203.	1.1	52
20	Ultrasensitive assessment of residual HIV viraemia in HAARTâ€treated patients with persistently undetectable plasma HIVâ€RNA: A crossâ€sectional evaluation. Journal of Medical Virology, 2009, 81, 400-405.	2.5	49
21	Targeting the NOâ€cGMPâ€PDE5 pathway in COVIDâ€19 infection. The DEDALO project. Andrology, 2021, 9, 33-38.	1.9	47
22	Taming HIV-Related Inflammation with Physical Activity: A Matter of Timing. AIDS Research and Human Retroviruses, 2014, 30, 936-944.	0.5	45
23	A pilot study on the effects of probiotic supplementation on neuropsychological performance and micro <scp>RNA</scp> â€1â€infected patients. Brain an Behavior, 2017, 7, e00756.	d.o	45
24	Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection. Blood, 2000, 96, 1979-1984.	0.6	42
25	Is teicoplanin a complementary treatment option for COVID-19? The question remains. International Journal of Antimicrobial Agents, 2020, 56, 106029.	1.1	41
26	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. International Journal of Antimicrobial Agents, 2019, 54, 728-734.	1.1	40
27	Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy?. Trends in Immunology, 2004, 25, 121-125.	2.9	39
28	Impact of High-Dose Multi-Strain Probiotic Supplementation on Neurocognitive Performance and Central Nervous System Immune Activation of HIV-1 Infected Individuals. Nutrients, 2017, 9, 1269.	1.7	38
29	HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. Current HIV Research, 2015, 13, 250-257.	0.2	37
30	Albumin Supplementation Dampens Hypercoagulability in COVID-19: A Preliminary Report. Thrombosis and Haemostasis, 2021, 121, 102-105.	1.8	36
31	Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 518-524.	0.9	35
32	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. PLoS ONE, 2013, 8, e80157.	1.1	35
33	Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19. Frontiers in Immunology, 2021, 12, 708149.	2.2	35
34	Rhabdomyolysis after cerivastatin–gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. Aids, 2001, 15, 820-821.	1.0	35
35	Ex Vivo and In Vitro Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Apoptosis. Journal of Infectious Diseases, 2000, 182, 1536-1539.	1.9	34
36	Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. BMC Infectious Diseases, 2017, 17, 581.	1.3	34

#	Article	IF	Citations
37	Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 319-329.	0.7	33
38	A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected Patients. Antiviral Therapy, 2019, 24, 63-67.	0.6	33
39	ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response. Immunobiology, 2016, 221, 282-290.	0.8	32
40	Probiotics and COVID-19. The Lancet Gastroenterology and Hepatology, 2020, 5, 721-722.	3.7	32
41	HIV-1 Residual Viremia and Proviral DNA in Patients with Suppressed Plasma Viral Load ( < 400) Tj ETQq1 1 0.78	4314 rgBT 0.2	JOverlock
42	Gut Microbial Translocation in Critically Ill Children and Effects of Supplementation with Pre- and Pro Biotics. International Journal of Microbiology, 2012, 2012, 1-8.	0.9	31
43	Severe and Persistent Depletion of Circulating Plasmacytoid Dendritic Cells in Patients with 2009 Pandemic H1N1 Infection. PLoS ONE, 2011, 6, e19872.	1.1	31
44	Type-specific human papillomavirus-DNA load in anal infection in HIV-positive men. Aids, 2008, 22, 1929-1935.	1.0	30
45	Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virus. Critical Care, 2019, 23, 330.	2.5	30
46	Normocaloric Low Cholesterol Diet Modulates Th17/Treg Balance in Patients with Chronic Hepatitis C Virus Infection. PLoS ONE, 2014, 9, e112346.	1.1	29
47	What happens to cardiovascular system behind the undetectable level of HIV viremia?. AIDS Research and Therapy, 2016, 13, 21.	0.7	29
48	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1955-1964.	1.3	29
49	Antiâ€IFNâ€Î±/â€Ï‰ neutralizing antibodies from COVIDâ€19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. European Journal of Immunology, 2022, 52, 1120-1128.	1.6	29
50	Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing. Journal of Clinical Microbiology, 2003, 41, 1760-1762.	1.8	28
51	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. Journal of Antimicrobial Chemotherapy, 2017, 72, 2055-2059.	1.3	28
52	Cardiac involvement in consecutive unselected hospitalized COVID-19 population: In-hospital evaluation and one-year follow-up. International Journal of Cardiology, 2021, 339, 235-242.	0.8	28
53	MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients. BMC Infectious Diseases, 2015, 15, 51.	1.3	26
54	Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). Virus Research, 2021, 295, 198283.	1.1	26

#	Article	IF	Citations
55	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE, 2014, 9, e109791.	1.1	26
56	Covidâ€19 sequelae in working age patients: A systematic review. Journal of Medical Virology, 2022, 94, 858-868.	2.5	26
57	Timed Short Messaging Service Improves Adherence and Virological Outcomes in HIV-1–Infected Patients With Suboptimal Adherence to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, e113-e115.	0.9	24
58	Significant coronary stenosis detected by coronary computed angiography in asymptomatic HIV infected subjects. Journal of Infection, 2012, 64, 82-88.	1.7	24
59	HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis. Vaccines, 2022, 10, 239.	2.1	24
60	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. Pharmacological Research, 2011, 63, 249-253.	3.1	23
61	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scandinavian Journal of Infectious Diseases. 2014, 46, 34-45.	1.5	23
62	Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Clinical Chemistry and Laboratory Medicine, 2014, 53, 567-73.	1.4	23
63	Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naà ve patients: results from a multicenter cohort study. Antiviral Research, 2019, 169, 104552.	1.9	23
64	Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. Journal of Medical Virology, 2007, 79, 880-886.	2.5	22
65	Expression Levels of TLRs Involved in Viral Recognition in PBMCs from HIV-1-Infected Patients Failing Antiretroviral Therapy. Intervirology, 2009, 52, 107-114.	1.2	22
66	Modulation of Tryptophan/Serotonin Pathway by Probiotic Supplementation in Human Immunodeficiency Virus–Positive Patients: Preliminary Results of a New Study Approach. International Journal of Tryptophan Research, 2017, 10, 117864691771066.	1.0	22
67	Ozone as adjuvant support in the treatment of COVIDâ€19: A preliminary report of probiozovid trial. Journal of Medical Virology, 2021, 93, 2210-2220.	2.5	22
68	Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection. Chemotherapy, 2021, 66, 24-32.	0.8	22
69	Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy. Journal of Clinical Microbiology, 2005, 43, 6183-6185.	1.8	21
70	Buschke-Löwenstein tumor with squamous cell carcinoma treated with chemo-radiation therapy and local surgical excision: report of three cases. World Journal of Surgical Oncology, 2013, 11, 231.	0.8	21
71	Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. Medical Microbiology and Immunology, 2014, 203, 207-16.	2.6	20
72	The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infectious Diseases, 2015, 15, 393.	1.3	20

#	Article	IF	CITATIONS
73	Infected chronic ischemic wound topically treated with a multi-strain probiotic formulation: a novel tailored treatment strategy. Journal of Translational Medicine, 2019, 17, 364.	1.8	20
74	JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis. Virology Journal, 2020, 17, 23.	1.4	20
75	The role of teicoplanin in the treatment of SARSâ€CoVâ€2 infection: A retrospective study in critically ill COVIDâ€19 patients (Teiâ€COVID study). Journal of Medical Virology, 2021, 93, 4319-4325.	2.5	20
76	Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortality. Internal and Emergency Medicine, 2021, 16, 1231-1237.	1.0	20
77	Interleukin-15 enhances the secretion of IFN- $\hat{l}^3$ and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunology Letters, 2006, 103, 192-195.	1.1	19
78	HIV-associated progressive multifocal leukoencephalopathy: longitudinal study of JC virus non-coding control region rearrangements and host immunity. Journal of NeuroVirology, 2013, 19, 274-279.	1.0	19
79	Many Different Patterns under a Common Flag: Aortic Pathology in HIV—A Review of Case Reports in Literature. Annals of Vascular Surgery, 2019, 59, 268-284.	0.4	19
80	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. Aids, 2019, 33, 759-762.	1.0	19
81	Discordant response to antiretroviral therapy. Aids, 2002, 16, 1877-1885.	1.0	18
82	Interleukin-15 modulates interferon- $\hat{l}^3$ and $\hat{l}^2$ -chemokine production in patients with HIV infection: implications for immune-based therapy. Cytokine, 2004, 25, 283-290.	1.4	18
83	Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study. International Journal of Molecular Sciences, 2016, 17, 1639.	1.8	18
84	Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection. Medicine (United States), 2020, 99, e21803.	0.4	18
85	Efficacy and durability of two― <i>vs</i> . threeâ€drug integrase inhibitorâ€based regimens in virologically suppressed HIVâ€infected patients: Data from realâ€ife ODOACRE cohort. HIV Medicine, 2021, 22, 843-853.	1.0	18
86	Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 234-237.	0.9	18
87	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. Thrombosis and Haemostasis, 2022, 122, 257-266.	1.8	18
88	Changes in Circulating Levels of Soluble Cell Adhesion Molecules Following Highly Active Antiretroviral Treatment of HIV-1-Infected Patients. Clinical Immunology, 2000, 95, 212-217.	1.4	17
89	Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Tropica, 2006, 99, 83-87.	0.9	16
90	Apoptosis-associated gene expression in HIV-infected patients in response to successful antiretroviral therapy. Journal of Medical Virology, 2007, 79, 111-117.	2.5	15

#	Article	IF	Citations
91	Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	15
92	Alzheimer's Dementia in People Living With HIV. Neurology: Clinical Practice, 2021, 11, 10.1212/CPJ.000000000001060.	0.8	15
93	Discordance between Genotypic and Phenotypic Drug Resistance Profiles in Human Immunodeficiency Virus Type 1 Strains Isolated from Peripheral Blood Mononuclear Cells. Journal of Clinical Microbiology, 2002, 40, 335-340.	1.8	14
94	High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic Analysis. Journal of Clinical Microbiology, 2003, 41, 3007-3012.	1.8	14
95	Urinary Schistosomiasis in Asylum Seekers in Italy: An Emergency Currently Undervalued. Journal of Immigrant and Minority Health, 2013, 15, 846-850.	0.8	14
96	Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients. PLoS ONE, 2016, 11, e0149601.	1.1	14
97	Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scandinavian Journal of Gastroenterology, 2016, 51, 1257-1262.	0.6	14
98	Type I/II Interferon in HIV-1-Infected Patients: Expression in Gut Mucosa and in Peripheral Blood Mononuclear Cells and Its Modification upon Probiotic Supplementation. Journal of Immunology Research, 2018, 2018, 1-7.	0.9	14
99	High abundance of genus Prevotella is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients. Aids, 2020, 34, 1467-1473.	1.0	14
100	Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review. Advances in Experimental Medicine and Biology, 2020, 1323, 103-114.	0.8	14
101	The importance of genomic analysis in cracking the coronavirus pandemic. Expert Review of Molecular Diagnostics, 2021, 21, 547-562.	1.5	14
102	Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 816-818.	0.5	13
103	Diagnostic Issues of Asymptomatic Neurosyphilis in HIV-Positive Patients: A Retrospective Study. Brain Sciences, 2019, 9, 278.	1.1	13
104	Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naÃ-ve patients: A single-centre experience. Journal of Global Antimicrobial Resistance, 2020, 20, 298-303.	0.9	13
105	Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-Like HIV-1 resistance mutations. Journal of Medical Virology, 2001, 65, 631-636.	2.5	12
106	Thymosin $\hat{l}\pm 1$ potentiates the release by CD8+cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infectionin vitro. Expert Opinion on Biological Therapy, 2015, 15, 83-100.	1.4	12
107	Increased expression of IL-32 correlates with IFN- $\hat{l}^3$ , Th1 and Tc1 in virologically suppressed HIV-1-infected patients. Cytokine, 2019, 120, 273-281.	1.4	12
108	Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience. Journal of Clinical Medicine, 2021, 10, 3784.	1.0	12

#	Article	IF	CITATIONS
109	Human immunodeficiency virus-1 specific and natural cellular immunity in HIV seronegative subjects with multiple sexual exposures to virus. Journal of Medical Virology, 2001, 64, 232-237.	2.5	11
110	Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir. Archives of Virology, 2017, 162, 2565-2577.	0.9	11
111	Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients. Biology of Sex Differences, 2020, 11, 23.	1.8	11
112	Superinfections in patients treated with Teicoplanin as antiâ€SARSâ€CoVâ€2 agent. European Journal of Clinical Investigation, 2021, 51, e13418.	1.7	11
113	Human Immunodeficiency Virus Type 2: The Neglected Threat. Pathogens, 2021, 10, 1377.	1.2	11
114	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. Journal of Antimicrobial Chemotherapy, 2013, 68, 193-199.	1.3	10
115	Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis. HIV Clinical Trials, 2016, 17, 49-54.	2.0	10
116	Is previous influenza-like illness a potential Trojan horse for COVID-19?. Critical Care, 2020, 24, 503.	2.5	10
117	Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients. Journal of Clinical Virology, 2020, 128, 104450.	1.6	10
118	Post-Traumatic Stress Disorder Trajectories the Year after COVID-19 Hospitalization. International Journal of Environmental Research and Public Health, 2022, 19, 8452.	1.2	10
119	Overexpression of Lymphocytic GD3 Ganglioside and Presence of Anti-GD3 Antibodies in Patients with HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1539-1549.	0.5	9
120	Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients. Journal of Antimicrobial Chemotherapy, 2004, 53, 494-500.	1.3	9
121	Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. Journal of Medical Case Reports, 2011, 5, 70.	0.4	9
122	Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens. AIDS Research and Human Retroviruses, 2015, 31, 71-77.	0.5	9
123	IFN-α promotes rapid human Treg contraction and late Th1-like Treg decrease. Journal of Leukocyte Biology, 2016, 100, 613-623.	1.5	9
124	Physical Activity and HIV: Effects on Fitness Status, Metabolism, Inflammation and Immune-Activation. AIDS and Behavior, 2020, 24, 1042-1050.	1.4	9
125	Cognitive impairment and CSF proteome modification after oral bacteriotherapy in HIV patients. Journal of NeuroVirology, 2020, 26, 95-106.	1.0	9
126	Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort. AIDS Research and Human Retroviruses, 2021, 37, 4-10.	0.5	9

#	Article	IF	Citations
127	Oxygen Sparing Effect of Bacteriotherapy in COVID-19. Nutrients, 2021, 13, 2898.	1.7	9
128	Depressive Symptoms among Individuals Hospitalized with COVID-19: Three-Month Follow-Up. Brain Sciences, 2021, 11, 1175.	1.1	9
129	Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. Diagnostics, 2022, 12, 76.	1.3	9
130	Microbial Translocation and Infectious Diseases: What Is the Link?. International Journal of Microbiology, 2012, 2012, 1-2.	0.9	8
131	Mobile Phone Microbial Contamination Among Neonatal Unit Healthcare Workers. Infection Control and Hospital Epidemiology, 2015, 36, 487-489.	1.0	8
132	Apoptotic Epitope–Specific CD8 <sup>+</sup> T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2016, 213, 674-683.	1.9	8
133	Impact of the 2017 measles outbreak on the emergency care system of a large tertiary-care teaching hospital in Italy: a retrospective analysis. European Journal of Public Health, 2019, 29, 966-971.	0.1	8
134	Myeloid and lymphoid activation markers in AIDS and non-AIDS presenters. Immunobiology, 2019, 224, 231-241.	0.8	8
135	High HIV-1 diversity in immigrants resident in Italy (2008–2017). Scientific Reports, 2020, 10, 3226.	1.6	8
136	Dysbiosis in SARS-CoV-2–Infected Patients. Gastroenterology, 2021, 160, 2195.	0.6	8
137	The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 803.	1.8	8
138	DC contact with HIVâ€1â€infected cells leads to high levels of Envâ€mediated virion endocytosis coupled with enhanced HIVâ€1 Ag presentation. European Journal of Immunology, 2009, 39, 404-416.	1.6	7
139	Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. BMC Infectious Diseases, 2011, 11, 341.	1.3	7
140	Trends in drug resistance-associated mutations in a real-life cohort of Italian patients infected with HIV-1. Journal of Global Antimicrobial Resistance, 2015, 3, 267-272.	0.9	7
141	Clearance of human papillomavirus related anal condylomas after oral and endorectal multistrain probiotic supplementation in an HIV positive male. Medicine (United States), 2018, 97, e0329.	0.4	7
142	Increased IL-17 and/or IFN- $\hat{I}^3$ producing T-cell subsets in gut mucosa of long-term-treated HIV-1-infected women. Aids, 2019, 33, 627-636.	1.0	7
143	Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients. Medical Microbiology and Immunology, 2019, 208, 679-691.	2.6	7
144	Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial. Metabolites, 2020, 10, 274.	1.3	7

#	Article	IF	Citations
145	Comparison Between Hospitalized Patients Affected or Not Affected by Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 72, e1158-e1159.	2.9	7
146	Surveillance of COVID-19 in migrant reception centres: a call for action. Journal of Travel Medicine, 2021, 28, .	1.4	7
147	Procalcitonin in daily clinical practice: an evergreen tool also during a pandemic. Internal and Emergency Medicine, 2021, 16, 541-543.	1.0	7
148	Viral community acquired pneumonia at the emergency department: Report from the pre COVIDâ€19 age. Journal of Medical Virology, 2021, 93, 4399-4404.	2.5	7
149	Fecal Microbial Transplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent Clostridium difficile infection patients. New Microbiologica, 2019, 42, 221-224.	0.1	7
150	Analysis of serum microRNAs and rs2910164 GC single-nucleotide polymorphism of miRNA-146a in COVID-19 patients. Journal of Immunoassay and Immunochemistry, 2022, 43, 347-364.	0.5	7
151	Neutralizing Antibodies against Autologous Human Immunodeficiency Virus Type 1 Isolates in Patients with Increasing CD4 Cell Counts despite Incomplete Virus Suppression during Antiretroviral Treatment. Vaccine Journal, 2001, 8, 822-824.	2.6	6
152	Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. Aids, 2005, 19, 841-842.	1.0	6
153	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. HIV Clinical Trials, 2007, 8, 182-188.	2.0	6
154	Mutational Resistance Pattern of HIV Type 1 in CD14 <sup>+</sup> Monocytes, CD4 <sup>+</sup> T Cells, and Plasma from Treated Patients. AIDS Research and Human Retroviruses, 2010, 26, 625-634.	0.5	6
155	Prevalence of Prolonged Amenorrhea in HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e19-e21.	0.9	6
156	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine, 2012, 57, 54-60.	1.4	6
157	An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis. AIDS Research and Human Retroviruses, 2013, 29, 1254-1259.	0.5	6
158	Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. Isrn Aids, 2013, 2013, 1-6.	2.5	6
159	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infectious Diseases, 2016, 16, 401.	1.3	6
160	Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study. Current HIV Research, 2017, 15, 355-360.	0.2	6
161	Short-Term Probiotic Administration Increases Fecal-Anti Candida Activity in Healthy Subjects. Microorganisms, 2019, 7, 162.	1.6	6
162	Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients. Frontiers in Nutrition, 2021, 8, 756177.	1.6	6

#	Article	lF	CITATIONS
163	Abdominal aortic mycotic aneurysm, psoas abscess, and aorto-bisiliac graft infection due to Salmonella typhimurium. Journal of Infection and Chemotherapy, 2005, 11, 297-299.	0.8	5
164	Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: case report and review of the literature. Cardiovascular Revascularization Medicine, 2011, 12, 262-265.	0.3	5
165	Dominant enrichment of phenotypically activated CD38 <sup>+</sup> HLA-DR <sup>+</sup> CD8 <sup>+</sup> T cells, rather than CD38 <sup>+</sup> HLA-DR <sup>+</sup> CD4 <sup>+</sup> T cells, in HIV/HCV coinfected patients on antiretroviral therapy. Journal of Medical Virology, 2016, 88, 1347-1356.	2.5	5
166	Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study. International Journal of STD and AIDS, 2016, 27, 638-643.	0.5	5
167	Carotid Artery Aneurysm in HIV: A Review of Case Reports in Literature. Annals of Vascular Surgery, 2020, 63, 409-426.	0.4	5
168	Alteration of type I interferon response is associated with subclinical atherosclerosis in virologically suppressed HIVâ€1â€infected male patients. Journal of Medical Virology, 2021, 93, 4930-4938.	2.5	5
169	Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. AIDS Research and Human Retroviruses, 2021, 37, 478-485.	0.5	5
170	Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. Viruses, 2022, 14, 163.	1.5	5
171	High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19. Clinical Immunology, 2022, 241, 109068.	1.4	5
172	Apoptotic Cell Signaling in Lymphocytes from HIV+ Patients during Successful Therapy. Annals of the New York Academy of Sciences, 2006, 1090, 130-137.	1.8	4
173	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. Journal of Interferon and Cytokine Research, 2014, 34, 35-40.	0.5	4
174	Dynamics of HIV DNA and Residual Viremia in Patients Treated With a Raltegravir-Containing Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, e18-e20.	0.9	4
175	Preventing influenza and influenza like illness during Covid-19 pandemic: A call for action. Early Human Development, 2022, 169, 105156.	0.8	4
176	Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort. Expert Review of Anti-Infective Therapy, 2020, 18, 485-492.	2.0	4
177	First report of spondylodiscitis caused by Bacillus circulans in an immunocompetent patient: Clinical case and review of the literature. IDCases, 2021, 23, e01058.	0.4	4
178	SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients. Microorganisms, 2021, 9, 93.	1.6	4
179	CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia. Infezioni in Medicina, 2021, 29, 408-415.	0.7	4
180	Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19. Microorganisms, 2022, 10, 363.	1.6	4

#	Article	IF	CITATIONS
181	Diagnosis of anal human papillomavirus infection: polymerase chain reaction or cytology?. International Journal of Infectious Diseases, 2011, 15, e232-e235.	1.5	3
182	Expression of the mRNA Levels for MDR1, MRP1, MRP4, and MRP5 IN HIV Antiretroviral Naive Patients: Follow-up at 48 Weeks After the Beginning of Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e54-e56.	0.9	3
183	IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. Archives of Virology, 2016, 161, 3263-3268.	0.9	3
184	HIV-2 Infection in a Migrant from Gambia: The History of the Disease Combined with Phylogenetic Analysis Revealed the Real Source of Infection. AIDS Research and Human Retroviruses, 2018, 34, 1090-1094.	0.5	3
185	qSOFA as a new community-acquired pneumonia severity score in the emergency setting. Emergency Medicine Journal, 2021, 38, 906-912.	0.4	3
186	Efficacy of Daptomycin-Containing Regimen for Treatment of Staphylococcal or Enterococcal Vertebral Osteomyelitis: A Prospective Clinical Experience. Antibiotics, 2020, 9, 889.	1.5	3
187	Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders. Advances in Experimental Medicine and Biology, 2021, , 17-32.	0.8	3
188	The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review. Current HIV Research, 2021, 19, 106-120.	0.2	3
189	KI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients. Microorganisms, 2021, 9, 1259.	1.6	3
190	Clinical Characteristics and Outcome of Patients with Suspected COVID-19 in Emergency Department (RESILIENCY Study II). Diagnostics, 2021, 11, 1368.	1.3	3
191	Viral growth assay to evaluate the replicative capacity of HIV-1 isolates. Journal of Virological Methods, 2004, 115, 199-205.	1.0	2
192	Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. Expert Opinion on Pharmacotherapy, 2006, 7, 2233-2241.	0.9	2
193	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. AIDS Research and Human Retroviruses, 2013, 29, 1365-1369.	0.5	2
194	Interferon lambda4 polymorphism is not associated with human papillomavirus infection outcome. Virus Genes, 2018, 54, 319-322.	0.7	2
195	Singleâ€Strain Versus Multistrain Probiotic Supplementation Treatment Strategy for Rheumatoid Arthritis: Comment on the Article by Marietta etÂal. Arthritis and Rheumatology, 2018, 70, 320-321.	2.9	2
196	Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help?. Antibiotics, 2020, 9, 644.	1.5	2
197	Antibacterial Effectiveness of Fecal Water and In Vitro Activity of a Multi-Strain Probiotic Formulation against Multi-Drug Resistant Microorganisms. Microorganisms, 2020, 8, 332.	1.6	2
198	Malaria in an asylum seeker paediatric liver transplant recipient: diagnostic challenges for migrant population. Journal of Infection in Developing Countries, 2021, 15, 172-178.	0.5	2

#	Article	IF	CITATIONS
199	SARS-CoV-2 Among Migrants Recently Arrived in Europe From Low- and Middle-Income Countries: Containment Strategies and Special Features of Management in Reception Centers. Frontiers in Public Health, 2021, 9, 735601.	1.3	2
200	Clinical Effects of Oral Bacteriotherapy on Anal HPV Infection and Related Dysplasia in HIV-Positive MSM: Results from the "HPVinHIV―Trial. Biomedicines, 2021, 9, 1738.	1.4	2
201	Monocyte absolute count as a preliminary tool to distinguish between SARS-CoV-2 and influenza A/B infections in patients requiring hospitalization. Infezioni in Medicina, 2020, 28, 534-538.	0.7	2
202	Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients Treated with Standard Dose of Dexamethasone or High Dose of Methylprednisolone. Biomedicines, 2022, 10, 1548.	1.4	2
203	Systemic adipokines, hepatokines and interleukin-6 in HCV-monoinfected and HCV/HIV coinfected patients treated with direct antiviral agents (DAAs). Clinics and Research in Hepatology and Gastroenterology, 2018, 42, e45-e48.	0.7	1
204	Antiretroviral Therapy Dampens Mucosal CD4+ T Lamina Propria Lymphocytes Immune Activation in Long-Term Treated People Living with HIV-1. Microorganisms, 2021, 9, 1624.	1.6	1
205	Antiviral Activity of Fecal Water Samples from HIV-1 Infected Subjects Treated with a Specific Probiotic Formulation. Current HIV Research, 2019, 17, 183-189.	0.2	1
206	Lesson learned from the 2017 measles outbreak in Italy: report from an emergency department. Infezioni in Medicina, 2021, 29, 252-258.	0.7	1
207	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. Sexually Transmitted Infections, 2022, , sextrans-2021-055289.	0.8	1
208	An epidemiological investigation to reconstruct a probable human immunodeficiency virus -1 transmission network: a case report. Journal of Medical Case Reports, 2015, 9, 253.	0.4	0
209	State of the Art of Dual Therapy in 2015. AIDS Reviews, 2017, 17, .	0.5	0
210	Early antibiotic treatment in emergency department: the critical balance. Internal and Emergency Medicine, 2021, 16, 1743-1745.	1.0	0
211	590 ACE-I and ARBS do not influence the chest CT presentation and 1-year survival of COVID-19 patients: Italian multicentre registry. European Heart Journal Supplements, 2021, 23, .	0.0	0